The Technical Analyst
Ibio Inc [IBIO]
Exchange: AMEX Industry: Biotechnology
Ibio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.60% $1.850
America/New_York / 10 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 15.93 mill |
| EPS: | -15.25 |
| P/E: | -0.120 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 8.61 mill |
| Avg Daily Volume: | 3.92 mill |
| RATING 2024-05-10 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.120 | sector: PE 12.30 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.120 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.556 - 2.14 ( +/- 15.89%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-25 | Duran Felipe | Buy | 35 800 | Stock Option (right to buy) |
| 2023-11-01 | Brenner Martin | Sell | 4 881 | Common Stock |
| 2023-10-03 | Brenner Martin | Sell | 5 267 | Common Stock |
| 2023-10-02 | Brenner Martin | Sell | 4 215 | Common Stock |
| 2023-08-28 | Brenner Martin | Sell | 5 011 | Common Stock |
| INSIDER POWER |
|---|
| 85.21 |
| Last 90 transactions |
| Buy: 50 021 245 | Sell: 29 398 433 |
Forecast:
16:00 - $1.880
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.880
Forecast 2: 16:00 - $1.880
Forecast 3: 16:00 - $1.880
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.850 (-1.60% ) |
| Volume | 0.0983 mill |
| Avg. Vol. | 3.92 mill |
| % of Avg. Vol | 2.51 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IBIO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IBIO
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
Last 10 Buy Signals
Latest Press Releases
2024-03-27 07:00:00 - Press Release
Ibio And Astralbio Announce Transformative Ai Drug Discovery Collaboration To Rapidly Develop Novel Antibodies For Obesity And Cardiometabolic Diseases
– leading ai and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments –
2024-03-26 19:35:00 - Press Release
Ibio Announces $15.0 Million Private Placement
– purchase price of $2.85 represents a premium of 148+% to last close – bryan, texas and san diego, march 26, 2024 (globe newswire) -- ibio, inc. (nysea:ibio) (“ibio” or the “company”), an ai-driven innovator of precision antibody immunotherapies, announces today that it has entered into a securities purchase agreement for a private investment in public equity (“pipe”) financing that is expected to result in gross proceeds to the company of approximately $15.0 million, before deducting placement agent fees and offering expenses. the fully subscribed pipe financing included participation from adar1 capital management, lynx1 capital management, ikarian capital and other institutional and accredited investors.
2024-02-26 07:45:00 - Press Release
Ibio Announces Sale Of Preclinical Pd-1 Agonist Antibody Program To Otsuka
– deal includes $1 million upfront and potential future milestone payments – – ibio's proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates – bryan, texas and san diego, feb. 26, 2024 (globe newswire) -- ibio, inc. (nysea:ibio) (“ibio” or the “company”), an ai-driven innovator of precision antibody immunotherapies, announces today that it has entered into an asset purchase agreement (“agreement”) with otsuka pharmaceutical co., ltd. (“otsuka”), pursuant to which otsuka acquired ibio's assets related to its early-stage programmed cell death protein 1 (“pd-1” ) agonist program.
2024-01-16 08:15:00 - Press Release
Ibio Announces Participation In 23rd Annual Peptalk Conference
- vp of platform technologies, matt greving, to give podium presentation on enhancing bispecific t-cell engager discovery and development with machine learning - - vp of platform technologies, matt greving, to give podium presentation on enhancing bispecific t-cell engager discovery and development with machine learning -
2023-12-26 07:15:00 - Press Release
Ibio Amends And Extends Maturity Of Credit Agreement
– extends maturity date to march 29, 2024 – – allows for more time to complete planned divestiture of legacy cdmo business - bryan, texas and san diego, dec. 26, 2023 (globe newswire) -- ibio, inc. (nysea:ibio) (“ibio” or the “company”), an ai-driven innovator of precision antibody immunotherapies, today announced its wholly owned subsidiary, ibio cdmo llc, and its lender, woodforest national bank (“woodforest”), have entered into an amendment (the “amendment”) to the credit agreement dated november 1, 2021 (the “agreement”), extending the agreement's maturity date from december 31, 2023 to the earlier march 29, 2024, or the acceleration of maturity of the term loan in accordance with the credit agreement...
Latest News
2024-04-05 14:35:10 - InvestorPlace
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
The healthcare industry has historically provided significant returns to investors, with a predicted CAGR of 12.71% until 2027. Although many successful and profitable companies experience a surge in stock price, the healthcare industry also has many stocks that plummet.
2024-03-27 14:43:59 - Invezz
iBio stock nearly tripled on Wednesday: here's why
Shares of iBio Inc (NYSEAMERICAN: IBIO) close to tripled on Wednesday after the biotechnology company announced a collaboration with AstralBio Inc.
2024-03-27 11:54:07 - Proactive Investors
iBio partners with AstralBio to develop obesity treatments using AI-driven platform
iBio, an AI-driven drug developer, shares surged more than 120% after it announced it has entered into a collaboration agreement with private biotech firm AstralBio to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions. The company said the collaboration brings together its ability to create antibodies against hard-to-drug targets using its patented Generative AI and machine learning platform with AstralBio's experience in biologics and drug development.
2024-03-27 10:04:37 - InvestorPlace
Why Is iBio (IBIO) Stock Up 125% Today?
iBio‘s (NYSEMKT: IBIO ) shares are trending, and IBIO stock is up 125% today after the firm used two of the market's favorite buzzwords — artificial intelligence (AI) and obesity drugs — in a press release that unveiled a new initiative. Specifically, the firm announced that its AI drug discovery platform would be used to develop obesity treatments.
2023-12-05 08:48:58 - InvestorPlace
Why Is iBio (IBIO) Stock Down 41% Today?
Ibio (NYSEMKT: IBIO ) stock is falling hard on Tuesday after the biotechnology company announced the pricing of a public share offering. That offering has the company selling 2.25 million shares of IBIO stock for $2 each.
2023-09-28 16:06:06 - InvestorPlace
Ticking Time Bombs: 3 Healthcare Stocks to Dump Before the Damage Is Done
The healthcare industry has historically provided significant returns to investors. And, it is currently boasting a compounding annual growth rate prediction of 10.4% until 2027.
2023-06-13 09:40:52 - InvestorPlace
Why Is iBio (IBIO) Stock Up 16% Today?
Ibio (NYSEMKT: IBIO ) stock is rising higher on Tuesday as investors react to the company reaching a research collaboration agreement with the NIH. This will see the company teaming up with the NIH's National Institute of Allergy and Infectious Diseases (NIAID).
2023-03-27 14:14:10 - PennyStocks
Penny Stocks To Buy Now? 3 Short Squeeze Stock To Watch
2023-03-20 18:20:26 - InvestorPlace
7 Stocks to Sell as Banks Melt Down
Peruse the Internet for investment guidance and you're likely to hear the adage that you shouldn't consider stocks to sell when faced with volatility. Rather, you should buy up assets and securities when there's blood on the streets.
2023-03-08 10:44:00 - PennyStocks
4 Top Penny Stocks To Watch With Big Biotech News This Quarter
4 biotech penny stocks to watch right now. The post 4 Top Penny Stocks To Watch With Big Biotech News This Quarter appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.